Royalty Pharma plc

Royalty Pharma Plc Class A's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Royalty Pharma Plc Class A has 445.75M shares outstanding.

As of June 30, 2026, Royalty Pharma Plc Class A maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.58, indicating elevated leverage, while an interest coverage ratio of 4.20 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A posted a return on equity (ROE) of 12.37, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.34 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.54, useful for judging operating efficiency across full business cycles. The company generates approximately 22.25M in revenue per employee across its workforce of 99.75, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A generated 2.22B in revenue and converted that into 713.37M in net income, yielding earnings per share of 2.12. EBITDA reached 1.33B, while operating income came in at 1.38B.

As of June 30, 2026, Royalty Pharma Plc Class A holds 1.51B in cash and equivalents against 7.84B in total debt, resulting in a net debt position of 7.13B. Total book value stands at 5.98B, with working capital of 992.28M providing operational flexibility.

Royalty Pharma Plc Class A produced 2.61B in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of 62.35 and net profit margin of 32.14 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Royalty Pharma Plc Class A paid dividends of 0.80 per share. The dividend payout ratio of 21.17 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.